Genome-wide analysis of DNA copy number alterations in early and advanced gastric cancers

Molecular Carcinogenesis

Volumn 56, Issue 2, 2017, Pages 527-537

  Arakawa, Noriyuki ^a   Sugai, Tamotsu ^a   Habano, Wataru ^a   Eizuka, Makoto ^a   Sugimoto, Ryo ^a   Akasaka, Risaburo ^a   Toya, Yosuke ^a   Yamamoto, Eiichiro ^b   Koeda, Keisuke ^a   Sasaki, Akira ^a   Matsumoto, Takayuki ^a   Suzuki, Hiromu ^b  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

copy neutral LOH; copy number alteration; gain; gastric cancer; loss of heterozygosity

Indexed keywords

DNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CELL ISOLATION; CHROMOSOME 10P; CHROMOSOME 10P15.1; CHROMOSOME 11P; CHROMOSOME 11P.12; CHROMOSOME 11P13; CHROMOSOME 11P14.1; CHROMOSOME 11Q; CHROMOSOME 11Q.13.3; CHROMOSOME 11Q11; CHROMOSOME 11Q14.3; CHROMOSOME 11Q15.3; CHROMOSOME 11Q21; CHROMOSOME 12P; CHROMOSOME 12P11.21; CHROMOSOME 12P13.33; CHROMOSOME 12Q; CHROMOSOME 12Q12; CHROMOSOME 12Q13.3; CHROMOSOME 12Q21.1; CHROMOSOME 12Q21.31; CHROMOSOME 12Q21.33; CHROMOSOME 12Q22; CHROMOSOME 12Q23.2; CHROMOSOME 12Q32.32; CHROMOSOME 14Q; CHROMOSOME 14Q11.2; CHROMOSOME 14Q13.2; CHROMOSOME 14Q13.3; CHROMOSOME 14Q21.1; CHROMOSOME 14Q21.3; CHROMOSOME 14Q23.2; CHROMOSOME 14Q32.11; CHROMOSOME 14Q32.33; CHROMOSOME 17P; CHROMOSOME 17P13.3; CHROMOSOME 1Q; CHROMOSOME 1Q24.2; CHROMOSOME 2Q; CHROMOSOME 2Q12.1; CHROMOSOME 3P; CHROMOSOME 3P12.3; CHROMOSOME 3P14.1; CHROMOSOME 5Q; CHROMOSOME 5Q11.1; CHROMOSOME 5Q11.2; CHROMOSOME 5Q13.3; CHROMOSOME 5Q33.3; CHROMOSOME 5Q35.1; CHROMOSOME 8Q; CHROMOSOME 8Q23.3; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPT CELL; DNA ISOLATION; EARLY CANCER; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; STOMACH CANCER; VERY ELDERLY; COPY NUMBER VARIATION; DISEASE COURSE; EARLY CANCER DIAGNOSIS; GENETICS; MIDDLE AGED; PATHOLOGY; STOMACH; STOMACH NEOPLASMS;

AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; STOMACH; STOMACH NEOPLASMS;

EID: 84983239040     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22514     Document Type: Article

References (51)

1. Montori G, Coccolini F, Ceresoli M, et al. The treatment of peritoneal carcinomatosis in advanced gastric cancer: State of the art. Int J Surg Oncol 2014; 2014:912418.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19:1893–1907.
3. Ferrasi AC, Pinheiro NA, Rabenhorst SH, et al. Helicobacter pylori and EBV in gastric carcinomas: Methylation status and microsatellite instability. World J Gastroenterol 2010; 16:312–319.
4. Sugimoto R, Sugai T, Habano W, et al. Clinicopathological and molecular alterations in early gastric cancers with the microsatellite instability-high phenotype. Int J Cancer 2016; 138:1689–1697.
5. Lim B, Kim JH, Kim M, Kim SY. Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer. World J Gastroenterol 2016; 22:1190–1201.
6. Liang L, Fang JY, Xu J. Gastric cancer and gene copy number variation: Emerging cancer drivers for targeted therapy. Oncogene 2016; 35:1475–1482.
7. Tsukamoto Y, Uchida T, Karnan S, et al. Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer. J Pathol 2008; 216:471–482.
8. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14:101–112.
9. Sugai T, Inomata M, Uesugi N, et al. Analysis of mucin, p53 protein and Ki-67 expressions in gastric differentiated-type intramucosal neoplastic lesions obtained from endoscopic mucosal resection samples: A proposal for a new classification of intramucosal neoplastic lesions based on nuclear atypia. Pathol Int 2004; 54:425–435.
10. Habano W, Sugai T, Nakamura S, Yoshida T. A novel method for gene analysis of colorectal carcinomas using a crypt isolation technique. Lab Invest 1996; 74:933–940.
11. Sawada T, Yamamoto E, Suzuki H, et al. Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization. Genes Chromosomes Cancer 2013; 52:140–149.
12. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513:202–209.
13. Tan P, Yeoh KG. Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology 2015; 149:1153–1162.
14. Sunakawa Y, Lenz HJ. Molecular classification of gastric adenocarcinoma: Translating new insights from the cancer genome atlas research network. Curr Treat Options Oncol 2015; 16:17.
15. Smith P, Nicholson LJ, Syed N, et al. Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clin Cancer Res 2007; 13:4061–4068.
16. Zhang R, Song C. Loss of CSMD1 or 2 may contribute to the poor prognosis of colorectal cancer patients. Tumour Biol 2014; 35:4419–4423.
17. Shull AY, Clendenning ML, Ghoshal-Gupta S, et al. Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients. PLoS ONE 2013; 8:e58731.
18. Xiao YP, Wu DY, Xu L, Xin Y. Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma. World J Gastroenterol 2006; 12:3766–3769.
19. Kim S, Lee J, Hong ME, et al. High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. PLoS ONE 2014; 9:e111693.
20. Calcagno DQ, Leal MF, Assumpcao PP, Smith MA, Burbano RR. MYC and gastric adenocarcinoma carcinogenesis. World J Gastroenterol 2008; 14:5962–5968.
21. Lee KS, Kwak Y, Nam KH, et al. c-MYC copy-number gain is an independent prognostic factor in patients with colorectal cancer. PLoS ONE 2015; 10:e0139727.
22. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487:330–337.
23. Darcy KM, Brady WE, Blancato JK, et al. Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecol Oncol 2009; 114:472–479.
24. Hayashi H, Arao T, Togashi Y, et al. The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. Oncogene 2015; 34:199–208.
25. Jin DH, Park SE, Lee J, et al. Copy number gains at 8q24 and 20q11-q13 in gastric cancer are more common in intestinal-Type than diffuse-type. PLoS ONE 2015; 10:e0137657.
26. Gumireddy K, Li A, Yan J, et al. Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step. EMBO J 2013; 32:2672–2684.
27. Ghadimi BM, Grade M, Liersch T, et al. Gain of chromosome 8q23-24 is a predictive marker for lymph node positivity in colorectal cancer. Clin Cancer Res 2003; 9:1808–1814.
28. Cappellesso R, Fassan M, Hanspeter E, et al. HER2 status in gastroesophageal cancer: A tissue microarray study of 1040 cases. Hum Pathol 2015; 46:665–672.
29. Stahl P, Seeschaaf C, Lebok P, et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol 2015; 15:7.
30. Gravalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19:1523–1529.
31. Chen W, Yuan L, Cai Y, et al. Identification of chromosomal copy number variations and novel candidate loci in hereditary nonpolyposis colorectal cancer with mismatch repair proficiency. Genomics 2013; 102:27–34.
32. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396:643–649.
33. Yang S, Li WS, Dong F, et al. KITLG is a novel target of miR-34c that is associated with the inhibition of growth and invasion in colorectal cancer cells. J Cell Mol Med 2014; 18:2092–2102.
34. Huang T, Qiu X, Xiao J, et al. The prognostic role of Leucine-rich repeat-containing G-protein-coupled receptor 5 in gastric cancer: A systematic review with meta-analysis. Clin Res Hepatol Gastroenterol 2016; 40:246–253.
35. Shiratsuchi I, Akagi Y, Kawahara A, et al. Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer. Anticancer Res 2011; 31:2541–2545.
36. Lenhart R, Kirov S, Desilva H, et al. Sensitivity of small cell lung cancer to BET inhibition is mediated by regulation of ASCL1 gene expression. Mol Cancer Ther 2015; 14:2167–2174.
37. Han F, Zhang L, Qiu W, Yi X. TRAF6 promotes the invasion and metastasis and predicts a poor prognosis in gastric cancer. Pathol Res Pract 2016; 212:31–37.
38. He M, Gao L, Zhang S, et al. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL. Gastric Cancer 2014; 17:431–441.
39. Wang YP, Song GH, Chen J, et al. Elevated OCT1 participates in colon tumorigenesis and independently predicts poor prognoses of colorectal cancer patients. Tumour Biol 2016; 37:3247–3255.
40. Zheng ZH, Sun XJ, Fu WN, et al. Decreased expression of DICER1 in gastric cancer. Chin Med J (Engl) 2007; 120:2099–2104.
41. Braconi C, Kogure T, Valeri N, et al. MicroRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011; 30:4750–4756.
42. Anwar SL, Krech T, Hasemeier B, et al. Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PLoS ONE 2012; 7:e49462.
43. Sciarra A, Monti S, Gentile V, et al. Chromogranin A expression in familial versus sporadic prostate cancer. Urology 2005; 66:1010–1014.
44. Zhou J, Lu S, Yang S, et al. MicroRNA-127 post-transcriptionally downregulates Sept7 and suppresses cell growth in hepatocellular carcinoma cells. Cell Physiol Biochem 2014; 33:1537–1546.
45. Feng L, Xie Y, Zhang H. Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microRNA-650. Biochem Biophys Res Commun 2011; 406:534–538.
46. Futagami S, Hiratsuka T, Shindo T, et al. Expression of apurinic/apyrimidinic endonuclease-1 (APE-1) in H. pylori-associated gastritis, gastric adenoma, and gastric cancer. Helicobacter 2008; 13:209–218.
47. Tian L, Suzuki M, Nakajima T, et al. Thoracic Surgery Group. Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: Association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation. Cancer 2008; 113:1396–1403.
48. Jiang Y, Li W, He X, Zhang H, Jiang F, Chen Z. Lgr5 expression is a valuable prognostic factor for colorectal cancer: Evidence from a meta-analysis. BMC Cancer 2016; 16:12.
49. Salomonsson A, Jönsson M, Isaksson S, et al. Histological specificity of alterations and expression of KIT and KITLG in non-small cell lung carcinoma. Genes Chromosomes Cancer 2013; 52:1088–1096.
50. Qian J, Kong X, Deng N, et al. OCT1 is a determinant of synbindin-related ERK signalling with independent prognostic significance in gastric cancer. Gut 2015; 64:37–48.
51. Figueiredo C, Costa S, Karameris A, Machado JC. Pathogenesis of gastric cancer. Helicobacter 2015; 20:30–35.